Reference:
1. Fereidan-Esfahani M, Mahmudi F, Jahansouz M, Weber MS, Rodriguez M.
Biomarkers in radiologically isolated syndrome: The missing piece in the
puzzle of treatment indication? Journal of the neurological sciences.
2017;375:129.
2. Wilken J, Traboulsee A, Nelson F, Ionete C, Kolind S, Fratto T, et
al. Longitudinal assessment of neurocognitive function in people with
relapsing multiple sclerosis initiating alemtuzumab in routine clinical
practice: LEM-COG study results. Multiple Sclerosis and Related
Disorders. 2023;73:104677.
3. Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: a review of efficacy
and risks in the treatment of relapsing remitting multiple sclerosis.
Ther Clin Risk Manag. 2017;13:871-9.
4. Tempark T, John S, Rerknimitr P, Satapornpong P, Sukasem C.
Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical
Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and
Pharmacogenomics. Front Pharmacol. 2022;13:832048.
5. Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, et al. A
distinctive form of immune thrombocytopenia in a phase 2 study of
alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Blood. 2011;118(24):6299-305.